Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 2 Talazoparib and Temozolomide
The RARE 2 trial, sponsored by the National Cancer Institute, is investigating the combination of talazoparib, a PARP inhibitor, and temozolomide, an alkylating agent, in patients with advanced rare solid tumors. This trial addresses a niche market segment with limited treatment options, potentially positioning the combination therapy as a viable treatment for patients with rare cancers that have progressed on standard therapies. The outcomes of this trial could influence competitive positioning against existing therapies and inform future development strategies for similar combinations in oncology. Given the rarity of the target patient population, successful results may lead to expedited regulatory pathways and increased interest from pharmaceutical partners seeking to expand their oncology portfolios.
Indication: Adrenal Gland Pheochromocytoma
Modality: small molecule
Target: Poly (ADP-ribose) polymerase (PARP) inhibition and DNA damage via alkylating agent mechanism.
Sponsor: National Cancer Institute (NCI)
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 02, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Poly (ADP-ribose) polymerase (PARP) inhibition and DNA damage via alkylating agent mechanism.
View original source fields
Condition raw: Adrenal Gland Pheochromocytoma, Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm, Paraganglioma
Condition normalized: Adrenal Gland Pheochromocytoma, Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm, Paraganglioma
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Poly (ADP-ribose) polymerase (PARP) inhibition and DNA damage via alkylating agent mechanism.
Target normalized: Poly (ADP-ribose) polymerase (PARP) inhibition and DNA damage via alkylating agent mechanism.